Product
Losmapimod
Aliases
Losmapimod oral tablet
4 clinical trials
2 indications
Indication
COVID-19Indication
Facioscapulohumeral Muscular DystrophyClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)Status: Terminated, Estimated PCD: 2021-03-31
Clinical trial
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) With ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)Status: Active (not recruiting), Estimated PCD: 2025-10-01